A5079762645- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer-related Molecular Pathways
- Cancer Diagnosis and Treatment
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Statistical Methods in Clinical Trials
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- PI3K/AKT/mTOR signaling in cancer
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Genetics, Bioinformatics, and Biomedical Research
- Colorectal and Anal Carcinomas
- Immune cells in cancer
- Neuroblastoma Research and Treatments
- Nuclear Structure and Function
- Cancer, Lipids, and Metabolism
The University of Texas MD Anderson Cancer Center
2016-2025
Advanced Cancer Therapeutics
2021
Thermo Fisher Scientific (United States)
2019
Scripps MD Anderson Cancer Center
2018
Philadelphia University
2008
Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve a major challenge for early-phase clinical trials, which is recruit who, while having failed previous treatments, nevertheless respond molecularly targeted drugs. We report findings of prospective, single-center study conducted with diverse refractory cancers who underwent comprehensive genomic profiling (CGP; next-generation...
<h3>Background</h3> Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated efficacy and safety pembrolizumab patients with metastatic <h3>Methods</h3> This pre-specified cohort single-center, investigator-initiated, phase II clinical trial using monotherapy malignancies. Patients must have had prior fail past 6 months before study enrollment. were enrolled from August 2016 to October...
Background Patients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients cancers. Methods In this open-label, phase 2 trial, whose tumors had progressed on standard therapies, if available, within the previous 6 months were enrolled nine tumor-specific cohorts a 10th cohort for other histologies. Pembrolizumab 200 mg was...
TP53 tumor-suppressor gene mutations are among the most frequent abnormalities in cancer, affecting approximately 40% of patients. Yet, there is no accepted way to target these alterations clinic. At same time, antagonists VEGFR or its ligand best-selling oncology drugs, with multiple, expensive compounds approved. Although only a subset patients benefit from antiangiogenesis agents, relevant biomarker has been identified. Interestingly, upregulate VEGF-A and VEGFR2. We prospectively...
Abstract Purpose: To determine whether the Royal Marsden Hospital (RMH; London, UK) prognostic score for phase I patients can be validated in a large group of individuals seen different center and other variables are also relevant, we present an analysis 1,181 treated MD Anderson Cancer Center (MDACC; Houston, TX) clinic. Experimental Design: Medical records consecutive who were on at least one trial clinic reviewed. Results: The median age was 58 years 50% women. number prior therapies four...
Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare endocrine malignancies that associated with high rates of morbidity mortality because their large tumor burden location, progression, release catecholamines. Systemic therapies for MPPGs limited. characterized by pseudohypoxia may prevent immune system recognition. We conducted a phase II clinical trial pembrolizumab in patients progressive MPPGs. The primary endpoint was the non-progression rate at 27 weeks. secondary...
We present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers.
Background Cancer of unknown primary (CUP) is an aggressive rare malignancy with limited treatment options. Data regarding clinical activity immune checkpoint inhibitors in CUP lacking. Therefore, we evaluated the efficacy pembrolizumab, a programmed cell death-1 inhibitor, patients CUP. Methods The study was designed as phase 2 basket trial for independent tumor cohorts including Adult who had progressed on previous systemic therapy, performance status 0/1 and measurable disease per...
Systemic treatments for angiosarcoma remains an area of unmet clinical need. The authors conducted this retrospective study to assess the activity checkpoint inhibitors in patients with angiosarcoma. primary objective was response rate, and secondary progression-free overall survival durations disease control rate.Patient data were obtained using University Texas MD Anderson Cancer Center Tumor Registry database. final population refined only include who had undergone pembrolizumab...
Abstract Background Sapanisertib is a potent ATP‐competitive, dual inhibitor of mTORC1/2. Ziv‐aflibercept recombinant fusion protein comprising human VEGF receptor extracellular domains fused to immunoglobulin G1. HIF‐1α inhibition in combination with anti‐angiogenic therapy promising anti‐tumor strategy. This Phase 1 dose‐escalation/expansion study assessed safety/ tolerability sapanisertib ziv‐aflibercept advanced solid tumors. Methods Fifty‐five patients heavily pre‐treated metastatic...
Abstract Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal SCC who were treated single-agent pembrolizumab as part phase II basket clinical trial evaluate efficacy safety. Two cases SCC, multiple prior lines systemic chemotherapy radiation, received pembrolizumab. One patient had significant reduction (81%) target tumor lesions treatment discontinuation at...
Introduction Uveal melanoma remains a disease with aggressive behavior and poor prognosis despite advances in clinical management. Because monotherapy immune checkpoint inhibitors has led to limited improvement response rates, combination other agents that act on the biological basis of oncogenesis been proposed as possible therapeutic strategy. Methods We designed phase 1b trial test safety tolerability selinexor patients advanced uveal melanoma. Patients received 60 mg PO twice weekly...
Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP8/9), has shown synergistic activity with immune checkpoint inhibitors in preclinical studies. This open label, phase 2 basket trial assessed the antitumor combining talabostat pembrolizumab (anti-programmed death-1 antibody) advanced solid tumor patients. The primary objective was assessment dose-limiting toxicity (DLT) rates first six patients (lead-in stage) response rate (efficacy stage; included cohort A...
ABSTRACT Background Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of proteins, including tumor suppressors, to cytoplasm. Preclinical data suggest combination SEL with checkpoint blockade may result in improved response immunotherapy. Methods NCT02419495 was multiarm phase IB study other standard regimens patients advanced malignancies. Arm M utilized twice weekly oral and intravenous nivolumab (NIVO). N NIVO plus ipilimumab (IPI). The primary objective this...
Abstract Background: As not all patients respond to immunotherapy, it is important identify who are likely benefit from treatment. Several factors such as hypoalbuminemia, elevated neutrophil counts, and increased LDH have been associated with poor response immunotherapy reduced survival outcomes. Similarly, liver metastases immune checkpoint inhibitors in melanoma non-small cell lung cancer. However, its impact across solid tumors the effect of location, number, size on treatment outcomes...
Abstract Background Checkpoint agonists utomilumab (4-1BB agonist) and ivuxolimab (OX40 enhance Teffector cell function. Preclinical studies suggest that combining these drugs with avelumab (anti-PD-L1 antibody) can potentially synergize this effect. In addition, tissue abscopal effects of radiation therapy may improve antigen presentation, complementing PD-L1 blockade. We conducted a single institution, open-label, multi-arm, non-randomized, phase 1/2 clinical trial in combination...
ABSTRACT Introduction Rare solid tumors account for one-quarter of cancers among adults in the United States, but few resources have been devoted to their treatment. We evaluated efficacy pembrolizumab, a programmed cell death-1 inhibitor, patients with rare tumors. Methods conducted phase 2 basket trial that included rare, advanced Patients were enrolled study nine tumor-specific and 10th cohort miscellaneous histologies. received pembrolizumab 200 mg intravenously every 21 days. The...
// Jennifer Wheler 1 , David Hong Stephen G. Swisher 2 Gerald Falchook Apostolia M. Tsimberidou Thorunn Helgason Aung Naing Bettzy Filip Janku Philip J. Stephens 3 Roman Yelensky Razelle Kurzrock 4 Department of Investigational Cancer Therapeutics – a Phase I Clinical Trials Program, The University Texas MD Anderson Center Thoracic and Cardiovascular Surgery, Foundation Medicine, California, San Diego Moores Center, Correspondence: Wheler, email: Keywords : advanced thymoma, mTOR inhibitors,...
Patients with metastatic triple-negative breast cancer (TNBC) have poor treatment outcomes. We reviewed the electronic records of consecutive patients TNBC treated in phase I clinic at MD Anderson Cancer Center (Houston, TX) between Augu st 2005 and May 2012. One hundred six received least 1 trial. Twelve 98 evaluable (12%) had either complete response (CR; n = 1), partial (PR; 7), or stable disease ≥ 6 months (SD; 4). on matched therapy (n 16) compared those nonmatched 90) improved SD...